Philip R. Mayeux, Ph.D.

Philip MayeuxProfessor and Vice Chair, Director of Education
Program Director of SPaT T32 Training Grant
Program Director, SURF Program
Phone: 501-686-8895
Fax: 501-686-5521


Ph.D. – Tulane University, 1987

Research Interests

Acute renal failure is a frequent and serious complication of septic shock in humans. My research is focused on the study of animal models of renal injury associated with sepsis. Studies are directed toward understanding the biochemical and physiological mechanisms triggered by sepsis that lead to cellular injury and organ failure. Our primary interests are in understanding the development of oxidant stress caused by reactive oxygen and nitrogen species as mediators of renal injury and evaluating new therapeutic approaches to prevent renal injury or accelerate recovery.

Meet Dr. Mayeux’s Research Team

Recent Research Support

Current Research
T32 GM106999 (Program Director)  (07/01/13 – 06/30/19)
“Systems Pharmacology and Toxicology Training Program”

Completed Research
R01 GM106419  NIH/NIGMS  (CoPI)  (02/01/14 – 01/31/18)
“Mitochondrial injury and repair in sepsis-induced acute kidney injury”

15GRNT2508025  American Heart Association  (PI)   (07/01/15 – 06/30/17)
“Preclinical studies in a rat pup model of infant sepsis-induced cardiorenal syndrome”

NIH/NIDDK R01 DK075991 (07/31/08 – 05/31/14)
“Mechanistic targets of intervention in sepsis-induced renal injury”


Sims CR, Singh SP, Mu S, Gokden N, Zakaria D, Nguyen TC, Mayeux PR. Rolipram improves outcome in a rat model of infant sepsis-induced cardiorenal syndrome. Front. Pharmacol. 8:237, 2017. PMC5413568

Sims CR, Nguyen TC, Mayeux PR. Could biomarkers direct therapy for the septic patient? J. Pharmacol. Exp. Ther. 357:228-239, 2016. PMID: 26857961

Smith JA, Mayeux PR, Schnellmann RG. Delayed MEK/ERK inhibition by trametinib attenuates systemic inflammatory responses and multi-organ injury in murine sepsis. Crit. Care Med. 44:e711-20, 2016. PMID: 27031380

Li Y, Hadden C, Cooper A, Ahmed A, Wu H, Lupashin V, Mayeux PR, Kilic F. Sepsis-induced elevation in plasma serotonin facilitates endothelial hyperpermeability. Sci. Rep. 6:22747, 2016. PMID: 26956613

Ince C, Mayeux PR, Nguyen T, Gomez H, Kellum JA, Ospina-Tascon GA, Hernandez G, Murray P, De Backer D. The endothelium in sepsis. Shock. 45:259-270, 2016. PMID: 26871664

Wang Z, Sims CR, Patil NK, Gokden N, Mayeux PR. Pharmacological targeting of sphingosine-1-phosphate receptor 1 improves the renal microcirculation during sepsis in the mouse. J Pharmacol. Exp. Ther. 352:61-66, 2015. PMID: 25355645

Sims CR, MacMillan-Crow LA, Mayeux PR. Targeting mitochondrial oxidants may facilitate recovery of renal function during infant sepsis. Clin. Pharmacol. Ther. 96:662-664, 2014. PMID: 52148376

Patil NK, Parajuli N, MacMillan-Crow LA, Mayeux PR. Inactivation of renal mitochondrial respiratory complexes and manganese superoxide dismutase during sepsis: mitochondrial-targeted antioxidant mitigates injury. Am. J. Physiol. Renal Physiol. 306:F734-F743, 2014. PMID: 24500690

Holthoff JH, Wang Z, Patil NK, Gokden N, Mayeux PR. Rolipram improves renal perfusion and function during sepsis in the mouse. J. Pharmacol. Exp. Ther. 347:357-364, 2013. PMID: 24018639

View Dr. Mayeux’s Publication List